News of Note—Pfizer results, GSK shortage and more

In this week's news of note, Pfizer's Prevnar posted a third-quarter sales increase due to government purchases. (Pixabay)

Here is some other vaccine news of note for the week:

> Pfizer's vaccine sales in the third quarter grew 12% to $1.85 billion. Prevnar 13 sales in the U.S. were up 12% due to the timing of government purchases. Release (PDF)

> Pharmacists in Canada are reporting a shortage of GlaxoSmithKline's hep A and B vaccine for travelers Twinrix. CBC article

> A subsidiary of South Korea's GC Pharma received approval to start phase 1 testing of a shingles vaccine. Release

> Enesi Pharma entered an R&D deal to work on vaccines against Chikungunya, Zika and peanut allergy. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.